GenKyoTex. An Innovative Approach for the Treatment of Pathologies Associated with Overproduction of Oxygen Radicals GenKyoTex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals.  GenKyoTex is the world leader for the development of NADPH oxidases inhibitors with first-in-class molecules. The innovative approach of Genkyotex is to develop targeted anti-oxidative therapy by blocking specifically at the source the production of reactive oxygen species(ROS). NADPH oxidase inhibitors as novel therapeutics will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety and efficacy over existing non-targeted antioxidative therapy (standard anti-oxidants/scavenger molecules) giving them a significant competitive advantage. GenKyoTex targets its technology initially to the development of Nox4 inhibitors for two life threatening diseases: an orphan disease, idiopathic pulmonary fibrosis (IPF) as well as metastatic renal cell carcinoma (RCC).